[The macrolide antibiotic rovamycin in the treatment of pneumonias].
A clinical trial was made of the efficacy of macrolide antibiotic rovamycin (spiromycin) in 30 patients (mean age 35 +/- 12 years) with moderate extrahospital pneumonia. In group I (12 patients) with affection of at least 2 lung segments rovamycin was intravenously infused for 3 days (3,000,000 IU 2 times a day), then given orally for 5 days (3,000,000 IU 2 times a day every 12 hours). 18 patients of group 2 with 1-2 affected lung segments received rovamycin per os for 5-7 days three times a day (9,000,000 IU a day). Pneumonia etiology was verified in 22 patients. Str. pneumonia, Hemophilus influenzae, Staph, aureus. Str. pyogenes were registered in 10, 3, 2, 2 cases, respectively. Five patients had associations of gram-positive and gram-negative bacteria. Hospital stay lasted 13.4 +/- 0.7 days. At the end of the second week of the treatment pneumonia resolved in 100% of patients. Rovamycin proved low toxic and well tolerated.
Gel'tser
B I
BI
Rubashek
I A
IA
Semisotova
E F
EF
Kramar
A V
AV
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology; D015572:Spiramycin / Q000009:adverse effects / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology
D000900:Anti-Bacterial Agents; D015572:Spiramycin
Makrolidnyĭ antibiotik rovamitsin pri lechenii pnevmoniĭ.